Qlucore
0.39 SEK
-12.56 %
Less than 1K followers
QCORE
First North Stockholm
IT Services
Technology
Overview
Financials & Estimates
Ownership
Dividend
Investor consensus
-12.56 %
-2.99 %
-21.69 %
-4.41 %
-46.21 %
-77.68 %
-94.78 %
-
-98.60 %
Qlucore develops AI-based software for use in the healthcare sector. The company's precision medicine solutions transform genetic data into decision-making data to create the right treatment for patients. The company's first diagnostic test – for blood cancer in children – has been approved and CE-marked. The company also has tests for lung cancer under development, and is developing the Qlucore Omics Explorer analysis software.
Read moreMarket cap
16.73M SEK
Turnover
3.9K SEK
Revenue
10.21M
EBIT %
-200.88 %
P/E
-
Dividend yield-%
-
Revenue and EBIT-%
Revenue M
EBIT-% (adj.)
EPS and dividend
EPS (adj.)
Dividend %
Financial calendar
28/5
2026
Annual report '26
10/9
2026
General meeting '26
All
Webcasts
Press releases
3rd party
ShowingAll content types
Interim report 1 May 2025 - 31 January 2026
Inbjudan till presentation med frågestund av Qlucores delårsrapport för perioden 1 maj 2025 – 31 januari 2026
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools